Nexalin Technology (NXL) Change in Accured Expenses (2022 - 2026)
Nexalin Technology's (NXL) quarterly Change in Accured Expenses came in at -$2489.0 in Q1 2026, down 195.84% year-on-year from $2597.0 in Q1 2025, and down 100.78% quarter-over-quarter from $318723.0 in Q4 2025.
Nexalin Technology (NXL) Change in Accured Expenses (2022 - 2026) Analysis & Trends
Nexalin Technology's Change in Accured Expenses history runs 5 years deep, the most recent figure standing at -$2489.0 for Q1 2026.
- On a quarterly basis, Change in Accured Expenses fell 195.84% year-over-year to -$2489.0 in Q1 2026; TTM through Mar 2026 was $246923.0, a 556.2% increase from a year earlier, with the FY2025 full-year figure at $252009.0, up 94.66% from the prior year.
- Change in Accured Expenses slipped to -$2489.0 in Q1 2026 per NXL's latest filing, from $318723.0 in the prior quarter.
- Across five years, Change in Accured Expenses topped out at $318723.0 in Q4 2025 and bottomed at -$230747.0 in Q2 2024.
- The 5-year median for Change in Accured Expenses is $5973.0 (2023), against an average of $18502.9.
- Across the five-year window, Change in Accured Expenses jumped 316.82% in 2023 and plunged 3963.17% in 2024, its largest moves.
- Year by year, Change in Accured Expenses stood at $97322.0 in 2022, then sank by 336.95% to -$230607.0 in 2023, then jumped by 211.83% to $257898.0 in 2024, then gained by 23.58% to $318723.0 in 2025, then plunged by 100.78% to -$2489.0 in 2026.
- Per Business Quant, the three latest NXL Change in Accured Expenses figures stand at -$2489.0 (Q1 2026), $318723.0 (Q4 2025), and -$47973.0 (Q3 2025).
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Accured Expenses (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 182.32 Bn | 175.02 Bn | 6.27 Bn | - |
| 2 | Stryker | 128.75 Bn | 125.88 Bn | 3.81 Bn | -654.00 Mn |
| 3 | Medtronic | 107.83 Bn | 98.61 Bn | 6.41 Bn | 123.00 Mn |
| 4 | Boston Scientific | 67.61 Bn | 66.15 Bn | 3.61 Bn | -512.00 Mn |
| 5 | Edwards Lifesciences | 48.13 Bn | 44.45 Bn | 1.29 Bn | -347.10 Mn |
| 6 | Dexcom | 28.26 Bn | 27.14 Bn | 750.30 Mn | 145.10 Mn |
| 7 | GE HealthCare Technologies | 27.78 Bn | 25.50 Bn | 1.98 Bn | -250.00 Mn |
| 8 | Smith & Nephew | 26.99 Bn | 26.41 Bn | - | - |
| 9 | Koninklijke Philips | 23.92 Bn | 20.80 Bn | 2.07 Bn | 21.07 Mn |
| 10 | Nexalin Technology | 9.07 Mn | 6.36 Mn | 13,133.00 | -2,489.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -2,489.00 |
| Mar 31, 2026 | -2,489.00 |
| Dec 31, 2025 | 318,723.00 |
| Dec 31, 2025 | 318,723.00 |
| Sep 30, 2025 | -47,973.00 |
| Sep 30, 2025 | -47,973.00 |
| Jun 30, 2025 | -21,338.00 |
| Jun 30, 2025 | -21,338.00 |
| Mar 31, 2025 | 2,597.00 |
| Mar 31, 2025 | 2,597.00 |
| Dec 31, 2024 | 257,898.00 |
| Dec 31, 2024 | 257,898.00 |
| Sep 30, 2024 | 7,881.00 |
| Sep 30, 2024 | 7,881.00 |
| Jun 30, 2024 | -230,747.00 |
| Jun 30, 2024 | -230,747.00 |
| Mar 31, 2024 | 94,429.00 |
| Mar 31, 2024 | 94,429.00 |
| Dec 31, 2023 | -230,607.00 |
| Dec 31, 2023 | -230,607.00 |